Research Summary

Phase 3 Trial Shows Mim8 Prophylaxis Reduces Bleeding in Patients With Hemophilia A

Anthony Calabro, MA

Key Highlights

  • Mim8 prophylaxis significantly reduced annualized bleeding rates compared with on-demand treatment, with reductions of up to 98.7%.
  • Mim8 demonstrated superior efficacy compared with clotting factor concentrate prophylaxis, reducing bleeding rates by up to 54.0%.
  • A majority of patients receiving Mim8 prophylaxis (64% to 95%) experienced zero treated bleeding events during the trial.
  • No thromboembolic events, hypersensitivity reactions, or clinically significant neutralizing anti-Mim8 antibodies were reported.

Mim8 (denecimig), a bispecific antibody designed to mimic activated factor VIII, significantly reduced bleeding events among patients with hemophilia A with or without inhibitors, according to a phase 3 randomized trial published in The New England Journal of Medicine. The FRONTIER2 trial showed that both once-weekly and once-monthly Mim8 prophylaxis were superior to on-demand treatment and clotting factor concentrate prophylaxis in lowering the annualized rate of treated bleeding events.

In this prospective, open-label, randomized, controlled trial, investigators enrolled patients aged 12 years or older with hemophilia A, with or without factor VIII inhibitors. Patients in the pretrial on-demand cohort were randomly assigned to continue on-demand treatment or receive Mim8 prophylaxis administered subcutaneously once weekly or once monthly. Patients in the pretrial prophylaxis cohort underwent a run-in phase with clotting factor concentrates before being randomly assigned to Mim8 once weekly or once monthly. Dosing was tiered according to body weight and delivered in a fixed subcutaneous injection volume. The primary end points were the annualized rates of treated bleeding events compared with on-demand treatment and with prior clotting factor prophylaxis.

Study Findings

Among patients previously receiving on-demand treatment, the estimated mean annualized rate of treated bleeding events was 0.57 (95% CI, 0.25–1.30) with once-weekly Mim8 and 0.20 (95% CI, 0.06–0.71) with once-monthly Mim8, compared with 15.76 (95% CI, 10.70–23.20) with continued on-demand treatment. These results corresponded to relative reductions of 96.4% and 98.7%, respectively (P<0.001 for both comparisons).

Among patients previously receiving clotting factor prophylaxis, the estimated mean annualized rate of treated bleeding events was 2.25 (95% CI, 1.37–3.71) with once-weekly Mim8 compared with 4.90 during the run-in phase (relative reduction, 54.0%; P=0.006). With once-monthly Mim8, the rate was 1.78 (95% CI, 1.18–2.71) compared with 3.12 during the run-in phase (relative reduction, 42.8%; P=0.006). Across treatment groups, 64% to 95% of patients receiving Mim8 reported zero treated bleeding events. Injection-site reactions occurred in 10% of patients (2.6% of injections) and were mild. No thromboembolic events or hypersensitivity reactions were observed, and anti-Mim8 antibodies did not show clinical evidence of neutralizing activity.

Clinical Implications

According to the study authors, these findings suggest that Mim8 prophylaxis provides superior bleeding prevention compared with both on-demand treatment and clotting factor concentrate prophylaxis in patients with hemophilia A, irrespective of inhibitor status. The authors also noted that less frequent dosing schedules may reduce treatment burden.

The study had several limitations, including its open-label design, reliance on patient-reported bleeding events, and a small proportion of patients with inhibitors in the pretrial prophylaxis cohort.

Expert Commentary

"Among patients with hemophilia A with or without inhibitors, Mim8 prophylaxis was superior to on-demand treatment and clotting factor concentrate prophylaxis regarding the annualized rate of treated bleeding events,” the researchers concluded.

Reference:
Mancuso ME, Chan AKC, Shanmukhaiah C, et al; FRONTIER2 Investigators. Mim8 bispecific antibody prophylaxis in hemophilia A with or without inhibitors. N Engl J Med. 2026;394(17):1696-1709. doi:10.1056/NEJMoa2517384